Doxorubicin-antioxidant co-drugs.
Doxorubicin-antioxidant multitarget compounds 6 and 7 were obtained by combining doxorubicin (DOX) with caffeic and ferulic acids through an ester linkage at C-14. The products were studied in in vitro models of cardiomyocytes and breast cancer cells, characterized by different degrees of resistance to DOX, due to different expressions of ATP binding cassette (ABC) transporters. Compound 7 was found to be less toxic than DOX in cardiomyocytes and to display the same possibly higher toxicity against the resistant breast cancer cells. This result shows that appropriate DOX-antioxidant co-drugs can limit the onset of cardiac damage, a significant side-effect of DOX, without impairing the antitumor activity of the parent antibiotic.
['Chegaev|Konstantin|K|', 'Riganti|Chiara|C|', 'Rolando|Barbara|B|', 'Lazzarato|Loretta|L|', 'Gazzano|Elena|E|', 'Guglielmo|Stefano|S|', 'Ghigo|Dario|D|', 'Fruttero|Roberta|R|', 'Gasco|Alberto|A|']
D000818:Animals D000975:Antioxidants D002460:Cell Line D045744:Cell Line, Tumor D002470:Cell Survival D004317:Doxorubicin D018432:Drug Resistance, Multiple D005260:Female D005786:Gene Expression Regulation D006801:Humans D015394:Molecular Structure D032383:Myocytes, Cardiac
Doxorubicin Ferulic acid ABC transporters Antioxidant Cardiotoxicity